AAMU
ANIP icon

Amundi Asset Management US’s ANI Pharmaceuticals ANIP Stock Holding History

Amundi Asset Management US’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-600
Closed -$197K – 1633
2018
Q4 		$197K Sell
600
-11,000
-95% -$577K ﹤0.01% 1392
2018
Q3 		$656K Sell
11,600
-600
-5% -$36.7K ﹤0.01% 1320
2018
Q2 		$815K Buy
+12,200
New +$762K ﹤0.01% 1286

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $85.4B AUM 91.09% 1-Year Est. Return
ICOM
Investment Counselors of Maryland Baltimore, Maryland $4.37B AUM 76.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Amundi Asset Management US's ANIP Position: Q1 2019 in Review

Amundi Asset Management US sold out of ANI Pharmaceuticals (ANIP) in Q1 2019, closing a stake of 600 shares — an estimated $197K sold.

Amundi Asset Management US first reported a position in ANIP in Q2 2018 and held it in 3 quarters. The position peaked at $815K in Q2 2018. 190 funds tracked by Wall St. Rank hold ANIP as of Q1 2019.

  • Amundi Asset Management US reported no remaining ANI Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Amundi Asset Management US sold 600 ANI Pharmaceuticals shares in Q1 2019, an estimated $197K.
  • Amundi Asset Management US first reported a position in ANI Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Amundi Asset Management US's ANI Pharmaceuticals position peaked at $815K in Q2 2018.
  • 190 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2019.

Based on Amundi Asset Management US's 13F filing for Q1 2019, filed 13 May 2019.